Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
60.3M
-
Number of holders
-
212
-
Total 13F shares, excl. options
-
64.1M
-
Shares change
-
+18.6M
-
Total reported value, excl. options
-
$3.43B
-
Value change
-
+$1B
-
Put/Call ratio
-
0.52
-
Number of buys
-
143
-
Number of sells
-
-63
-
Price
-
$53.54
Significant Holders of Janux Therapeutics, Inc. - Common Stock (JANX) as of Q4 2024
251 filings reported holding JANX - Janux Therapeutics, Inc. - Common Stock as of Q4 2024.
Janux Therapeutics, Inc. - Common Stock (JANX) has 212 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 64.1M shares
.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (10.4M shares), FMR LLC (8.67M shares), JANUS HENDERSON GROUP PLC (3.56M shares), Paradigm Biocapital Advisors LP (3.52M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.06M shares), BlackRock, Inc. (2.73M shares), VANGUARD GROUP INC (2.14M shares), Cormorant Asset Management, LP (2.1M shares), Woodline Partners LP (1.85M shares), and EcoR1 Capital, LLC (1.47M shares).
This table shows the top 212 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.